[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWxRcd--8DTDlrMdKGT02VYqICfyehPaeR5CtfmTL3B4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":81,"rows":88},"Hospital Israelita Albert Einstein",[4],147,false,33,18,2253794,12,114,[14,17,19,22,25,27,29,31],{"name":15,"count":16},"Emotional Stress",5,{"name":18,"count":16},"Hypertension",{"name":20,"count":21},"Cardiovascular Diseases",4,{"name":23,"count":24},"Stroke",3,{"name":26,"count":24},"Sepsis",{"name":28,"count":24},"Covid19",{"name":30,"count":24},"Cancer",{"name":32,"count":24},"Acute Coronary Syndrome",[34,39,44,49,54,59,63,68,73,78],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03818334","Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies","2021-11-01","Cyclophosphamide",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05767723","Platelet Sub-study of the Neomindset Trial","2025-05-30","Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06011486","Expansion of Virus-Specific Lymphocytes for Cell Therapy","2025-06-10","Lymphocyte",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07053228","e-Natureza Blue Care: Nature-based Virtual Reality and Pain Perception","2025-12-15","Standard Pain Management",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04036409","Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients","2026-05-28","Intensive Control of Systolic Blood Pressure",{"nctId":60,"briefTitle":61,"date":62,"intervention":58},"NCT04040634","Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","2026-05-31",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05492123","Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","2026-12-31","Nivolumab 40 mg in 4 ml",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07341022","STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE","2027-12","Plerixafor Dose Escalation",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT07101822","A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED\u002FRECURRENT PENILE CANCER","2028-12","Cemiplimab",{"nctId":79,"briefTitle":80,"date":76,"intervention":77},"NCT07101848","A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED\u002FRECURRENT VULVAR CANCER",[82,83,84,85,86,87],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[89,114,132,160,178,207,230,248,269,292,325,347,370,405,432,450,476,503,528,546,570,595,621,639,665,691,709,736,763,781,810,828,855,873,912,946,964,982,1000,1018,1036,1054,1072,1090,1115,1142,1160,1185,1211],{"intervention":43,"totalTrials":90,"cells":91},1,{"EARLY_PHASE1":92,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":112},{"trials":93,"activeCount":94},[],0,{"trials":96,"activeCount":94},[],{"trials":98,"activeCount":94},[],{"trials":100,"activeCount":94},[],{"trials":102,"activeCount":90,"soonestReadout":42},[103],{"nctId":40,"briefTitle":41,"status":104,"phases":105,"primaryCompletion":42,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":110},"ACTIVE_NOT_RECRUITING",[86],"2025-06-30","2023-02-06",48,[32],[43,111],"Monotherapy: Ticagrelor alone OR Prasugrel alone",{"trials":113,"activeCount":94},[],{"intervention":111,"totalTrials":90,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":124,"NA":130},{"trials":117,"activeCount":94},[],{"trials":119,"activeCount":94},[],{"trials":121,"activeCount":94},[],{"trials":123,"activeCount":94},[],{"trials":125,"activeCount":90,"soonestReadout":42},[126],{"nctId":40,"briefTitle":41,"status":104,"phases":127,"primaryCompletion":42,"completion":106,"start":107,"enrollment":108,"conditions":128,"interventions":129},[86],[32],[43,111],{"trials":131,"activeCount":94},[],{"intervention":38,"totalTrials":90,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":156,"NA":158},{"trials":135,"activeCount":94},[],{"trials":137,"activeCount":94},[],{"trials":139,"activeCount":94},[],{"trials":141,"activeCount":90,"soonestReadout":37},[142],{"nctId":35,"briefTitle":36,"status":143,"phases":144,"primaryCompletion":37,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":154},"RECRUITING",[84,85],"2026-11-01","2018-11-06",50,[149,150,151,152,153],"Bone Marrow Transplant Complications","Graft Versus Host Disease","Infection Viral","Engraft Failure","Immunologic Suppression",[38,155],"ATG",{"trials":157,"activeCount":94},[],{"trials":159,"activeCount":94},[],{"intervention":155,"totalTrials":90,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":174,"NA":176},{"trials":163,"activeCount":94},[],{"trials":165,"activeCount":94},[],{"trials":167,"activeCount":94},[],{"trials":169,"activeCount":90,"soonestReadout":37},[170],{"nctId":35,"briefTitle":36,"status":143,"phases":171,"primaryCompletion":37,"completion":145,"start":146,"enrollment":147,"conditions":172,"interventions":173},[84,85],[149,150,151,152,153],[38,155],{"trials":175,"activeCount":94},[],{"trials":177,"activeCount":94},[],{"intervention":77,"totalTrials":179,"cells":180},2,{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":182,"activeCount":94},[],{"trials":184,"activeCount":94},[],{"trials":186,"activeCount":179,"soonestReadout":76},[187,195],{"nctId":74,"briefTitle":75,"status":188,"phases":189,"primaryCompletion":76,"completion":76,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NOT_YET_RECRUITING",[84],"2025-12",42,[193],"Penile Cancer",[77],{"nctId":79,"briefTitle":80,"status":188,"phases":196,"primaryCompletion":76,"completion":76,"start":197,"enrollment":191,"conditions":198,"interventions":200},[84],"2025-11-01",[199],"Vulvar Cancers",[77],{"trials":202,"activeCount":94},[],{"trials":204,"activeCount":94},[],{"trials":206,"activeCount":94},[],{"intervention":67,"totalTrials":90,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":210,"activeCount":94},[],{"trials":212,"activeCount":94},[],{"trials":214,"activeCount":90,"soonestReadout":66},[215],{"nctId":64,"briefTitle":65,"status":143,"phases":216,"primaryCompletion":66,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},[84],"2028-03-31","2022-08-30",112,[221],"Uterine Cervical Neoplasms",[67,223],"Ipilimumab 200 MG in 40 ML",{"trials":225,"activeCount":94},[],{"trials":227,"activeCount":94},[],{"trials":229,"activeCount":94},[],{"intervention":223,"totalTrials":90,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":242,"PHASE4":244,"NA":246},{"trials":233,"activeCount":94},[],{"trials":235,"activeCount":94},[],{"trials":237,"activeCount":90,"soonestReadout":66},[238],{"nctId":64,"briefTitle":65,"status":143,"phases":239,"primaryCompletion":66,"completion":217,"start":218,"enrollment":219,"conditions":240,"interventions":241},[84],[221],[67,223],{"trials":243,"activeCount":94},[],{"trials":245,"activeCount":94},[],{"trials":247,"activeCount":94},[],{"intervention":72,"totalTrials":90,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":263,"PHASE4":265,"NA":267},{"trials":251,"activeCount":94},[],{"trials":253,"activeCount":94},[],{"trials":255,"activeCount":90,"soonestReadout":71},[256],{"nctId":69,"briefTitle":70,"status":188,"phases":257,"primaryCompletion":71,"completion":258,"start":259,"enrollment":11,"conditions":260,"interventions":262},[83,84],"2028-06","2026-06-01",[261],"Sickle Cell Disease",[72],{"trials":264,"activeCount":94},[],{"trials":266,"activeCount":94},[],{"trials":268,"activeCount":94},[],{"intervention":48,"totalTrials":90,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":290},{"trials":272,"activeCount":94},[],{"trials":274,"activeCount":90,"soonestReadout":47},[275],{"nctId":45,"briefTitle":46,"status":143,"phases":276,"primaryCompletion":47,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":283},[83],"2026-06-10","2024-06-10",10,[281,282],"CMV Viremia","CMV",[48],{"trials":285,"activeCount":94},[],{"trials":287,"activeCount":94},[],{"trials":289,"activeCount":94},[],{"trials":291,"activeCount":94},[],{"intervention":58,"totalTrials":179,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":304},{"trials":295,"activeCount":94},[],{"trials":297,"activeCount":94},[],{"trials":299,"activeCount":94},[],{"trials":301,"activeCount":94},[],{"trials":303,"activeCount":94},[],{"trials":305,"activeCount":179,"soonestReadout":57},[306,317],{"nctId":55,"briefTitle":56,"status":104,"phases":307,"primaryCompletion":57,"completion":57,"start":308,"enrollment":309,"conditions":310,"interventions":315},[87],"2019-08-05",4368,[311,312,313,314],"Ischemic Stroke","Blood Pressure","Cognitive Impairment","Vascular Diseases",[58,316],"Standard control of Systolic Blood Pressure",{"nctId":60,"briefTitle":61,"status":104,"phases":318,"primaryCompletion":62,"completion":62,"start":319,"enrollment":320,"conditions":321,"interventions":324},[87],"2019-08-08",9476,[322,323,20,313],"Diabetes Mellitus","High Blood Pressure",[58,316],{"intervention":316,"totalTrials":179,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":337},{"trials":328,"activeCount":94},[],{"trials":330,"activeCount":94},[],{"trials":332,"activeCount":94},[],{"trials":334,"activeCount":94},[],{"trials":336,"activeCount":94},[],{"trials":338,"activeCount":179,"soonestReadout":57},[339,343],{"nctId":55,"briefTitle":56,"status":104,"phases":340,"primaryCompletion":57,"completion":57,"start":308,"enrollment":309,"conditions":341,"interventions":342},[87],[311,312,313,314],[58,316],{"nctId":60,"briefTitle":61,"status":104,"phases":344,"primaryCompletion":62,"completion":62,"start":319,"enrollment":320,"conditions":345,"interventions":346},[87],[322,323,20,313],[58,316],{"intervention":53,"totalTrials":90,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":350,"activeCount":94},[],{"trials":352,"activeCount":94},[],{"trials":354,"activeCount":94},[],{"trials":356,"activeCount":94},[],{"trials":358,"activeCount":94},[],{"trials":360,"activeCount":90,"soonestReadout":52},[361],{"nctId":50,"briefTitle":51,"status":188,"phases":362,"primaryCompletion":52,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":369},[87],"2026-03-30","2025-08-15",130,[367,368],"Cancer Pain","Palliative Care",[53],{"intervention":371,"totalTrials":179,"cells":372},"Leronlimab",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":401,"NA":403},{"trials":374,"activeCount":94},[],{"trials":376,"activeCount":94},[],{"trials":378,"activeCount":94},[],{"trials":380,"activeCount":94},[381,393],{"nctId":382,"briefTitle":383,"status":384,"phases":385,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT04901676","Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia","SUSPENDED",[85],"2023-01","2023-02","2021-09-09",612,[391],"COVID-19 Pneumonia",[371],{"nctId":394,"briefTitle":395,"status":384,"phases":396,"primaryCompletion":387,"completion":387,"start":397,"enrollment":398,"conditions":399,"interventions":400},"NCT04901689","Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation",[85],"2021-10-23",316,[391],[371],{"trials":402,"activeCount":94},[],{"trials":404,"activeCount":94},[],{"intervention":406,"totalTrials":90,"cells":407},"Diaper with a copper-based product + usual care",{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":428,"NA":430},{"trials":409,"activeCount":94},[],{"trials":411,"activeCount":94},[],{"trials":413,"activeCount":94},[],{"trials":415,"activeCount":94},[416],{"nctId":417,"briefTitle":418,"status":419,"phases":420,"primaryCompletion":421,"completion":422,"start":423,"enrollment":94,"conditions":424,"interventions":426},"NCT06726707","COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis","WITHDRAWN",[84,85],"2026-06-30","2026-08-30","2025-09-01",[425],"Incontinence-associated Dermatitis",[406,427],"Barrier product with common diaper",{"trials":429,"activeCount":94},[],{"trials":431,"activeCount":94},[],{"intervention":427,"totalTrials":90,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":446,"NA":448},{"trials":435,"activeCount":94},[],{"trials":437,"activeCount":94},[],{"trials":439,"activeCount":94},[],{"trials":441,"activeCount":94},[442],{"nctId":417,"briefTitle":418,"status":419,"phases":443,"primaryCompletion":421,"completion":422,"start":423,"enrollment":94,"conditions":444,"interventions":445},[84,85],[425],[406,427],{"trials":447,"activeCount":94},[],{"trials":449,"activeCount":94},[],{"intervention":451,"totalTrials":90,"cells":452},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":472,"NA":474},{"trials":454,"activeCount":94},[],{"trials":456,"activeCount":94},[],{"trials":458,"activeCount":94},[],{"trials":460,"activeCount":94},[461],{"nctId":462,"briefTitle":463,"status":464,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT05558098","Dapagliflozin in Patients With Critical Illness","COMPLETED",[85],"2023-10-20","2022-11-01",507,[470,26],"Critical Illness",[451],{"trials":473,"activeCount":94},[],{"trials":475,"activeCount":94},[],{"intervention":477,"totalTrials":90,"cells":478},"Melatonin 5 mg",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":499,"NA":501},{"trials":480,"activeCount":94},[],{"trials":482,"activeCount":94},[],{"trials":484,"activeCount":94},[],{"trials":486,"activeCount":94},[487],{"nctId":488,"briefTitle":489,"status":490,"phases":491,"primaryCompletion":492,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT03062839","Melatonin as Adjuvant Treatment for ADHD in Adults","UNKNOWN",[85],"2019-02-28","2019-06-30","2017-09-01",120,[497],"Attention Deficit Hyperactivity Disorder",[477],{"trials":500,"activeCount":94},[],{"trials":502,"activeCount":94},[],{"intervention":504,"totalTrials":90,"cells":505},"Double Dose Quadrivalent Influenza Vaccine",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":524,"NA":526},{"trials":507,"activeCount":94},[],{"trials":509,"activeCount":94},[],{"trials":511,"activeCount":94},[],{"trials":513,"activeCount":94},[514],{"nctId":515,"briefTitle":516,"status":464,"phases":517,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":522},"NCT04001504","Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes",[85],"2022-08-28","2019-07-19",1801,[32],[504,523],"Standard Dose Quadrivalent Influenza Vaccine",{"trials":525,"activeCount":94},[],{"trials":527,"activeCount":94},[],{"intervention":523,"totalTrials":90,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":94},[],{"trials":533,"activeCount":94},[],{"trials":535,"activeCount":94},[],{"trials":537,"activeCount":94},[538],{"nctId":515,"briefTitle":516,"status":464,"phases":539,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":540,"interventions":541},[85],[32],[504,523],{"trials":543,"activeCount":94},[],{"trials":545,"activeCount":94},[],{"intervention":547,"totalTrials":90,"cells":548},"Tofacitinib 10 mg",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":566,"NA":568},{"trials":550,"activeCount":94},[],{"trials":552,"activeCount":94},[],{"trials":554,"activeCount":94},[],{"trials":556,"activeCount":94},[557],{"nctId":558,"briefTitle":559,"status":464,"phases":560,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":565},"NCT04469114","Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia",[85],"2021-01-09","2020-09-16",289,[28],[547],{"trials":567,"activeCount":94},[],{"trials":569,"activeCount":94},[],{"intervention":571,"totalTrials":90,"cells":572},"Antiplatelet Monotherapy",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":591,"NA":593},{"trials":574,"activeCount":94},[],{"trials":576,"activeCount":94},[],{"trials":578,"activeCount":94},[],{"trials":580,"activeCount":94},[581],{"nctId":582,"briefTitle":583,"status":464,"phases":584,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":590},"NCT04360720","Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes",[85],"2024-11-30","2024-12-30","2020-10-15",3410,[32],[571],{"trials":592,"activeCount":94},[],{"trials":594,"activeCount":94},[],{"intervention":596,"totalTrials":90,"cells":597},"Zinc toothpaste",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":617,"NA":619},{"trials":599,"activeCount":94},[],{"trials":601,"activeCount":94},[],{"trials":603,"activeCount":94},[],{"trials":605,"activeCount":94},[606],{"nctId":607,"briefTitle":608,"status":490,"phases":609,"primaryCompletion":610,"completion":611,"start":612,"enrollment":365,"conditions":613,"interventions":615},"NCT05628571","Evaluation of the Antibacterial Effect of a Toothpaste Containing Zinc Lactate",[85],"2023-04-30","2023-06-30","2023-02-01",[614],"Oral Bacterial Infection",[596,616],"Fluoride Toothpaste",{"trials":618,"activeCount":94},[],{"trials":620,"activeCount":94},[],{"intervention":616,"totalTrials":90,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":635,"NA":637},{"trials":624,"activeCount":94},[],{"trials":626,"activeCount":94},[],{"trials":628,"activeCount":94},[],{"trials":630,"activeCount":94},[631],{"nctId":607,"briefTitle":608,"status":490,"phases":632,"primaryCompletion":610,"completion":611,"start":612,"enrollment":365,"conditions":633,"interventions":634},[85],[614],[596,616],{"trials":636,"activeCount":94},[],{"trials":638,"activeCount":94},[],{"intervention":640,"totalTrials":90,"cells":641},"Folfirinox",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":661,"NA":663},{"trials":643,"activeCount":94},[],{"trials":645,"activeCount":94},[],{"trials":647,"activeCount":94},[],{"trials":649,"activeCount":94},[650],{"nctId":651,"briefTitle":652,"status":490,"phases":653,"primaryCompletion":654,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":660},"NCT05081687","Brazilian Total Neoadjuvant Therapy Trial",[85],"2023-11-30","2023-12-30","2020-02-20",150,[659],"Colorectal Neoplasms",[640],{"trials":662,"activeCount":94},[],{"trials":664,"activeCount":94},[],{"intervention":666,"totalTrials":90,"cells":667},"candesartan cilexetil + chlorthalidone + amlodipine",{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":687,"NA":689},{"trials":669,"activeCount":94},[],{"trials":671,"activeCount":94},[],{"trials":673,"activeCount":94},[],{"trials":675,"activeCount":94},[676],{"nctId":677,"briefTitle":678,"status":464,"phases":679,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":685},"NCT05920005","Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension",[85],"2025-03-31","2025-05-01","2023-08-22",702,[18],[666,686],"Exforge HCT®",{"trials":688,"activeCount":94},[],{"trials":690,"activeCount":94},[],{"intervention":686,"totalTrials":90,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":705,"NA":707},{"trials":694,"activeCount":94},[],{"trials":696,"activeCount":94},[],{"trials":698,"activeCount":94},[],{"trials":700,"activeCount":94},[701],{"nctId":677,"briefTitle":678,"status":464,"phases":702,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":703,"interventions":704},[85],[18],[666,686],{"trials":706,"activeCount":94},[],{"trials":708,"activeCount":94},[],{"intervention":710,"totalTrials":90,"cells":711},"Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133\u002F66\u002F4mg",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":732,"NA":734},{"trials":713,"activeCount":94},[],{"trials":715,"activeCount":94},[],{"trials":717,"activeCount":94},[],{"trials":719,"activeCount":94},[720],{"nctId":721,"briefTitle":722,"status":723,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":731},"NCT04989413","Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -","TERMINATED",[84,85],"2025-02-20","2022-10-18",110,[729,730],"Chronic Migraine, Headache","Overuse Headache Medication",[710],{"trials":733,"activeCount":94},[],{"trials":735,"activeCount":94},[],{"intervention":737,"totalTrials":90,"cells":738},"Amitriptyline",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":759,"NA":761},{"trials":740,"activeCount":94},[],{"trials":742,"activeCount":94},[],{"trials":744,"activeCount":94},[],{"trials":746,"activeCount":94},[747],{"nctId":748,"briefTitle":749,"status":464,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":754,"conditions":755,"interventions":757},"NCT01357031","Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine",[85],"2011-12","2012-12","2010-05",192,[756],"Migraine",[737,758],"Melatonin",{"trials":760,"activeCount":94},[],{"trials":762,"activeCount":94},[],{"intervention":758,"totalTrials":90,"cells":764},{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":771,"PHASE4":777,"NA":779},{"trials":766,"activeCount":94},[],{"trials":768,"activeCount":94},[],{"trials":770,"activeCount":94},[],{"trials":772,"activeCount":94},[773],{"nctId":748,"briefTitle":749,"status":464,"phases":774,"primaryCompletion":751,"completion":752,"start":753,"enrollment":754,"conditions":775,"interventions":776},[85],[756],[737,758],{"trials":778,"activeCount":94},[],{"trials":780,"activeCount":94},[],{"intervention":782,"totalTrials":90,"cells":783},"ARM A Cyclophosphamide",{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":806,"NA":808},{"trials":785,"activeCount":94},[],{"trials":787,"activeCount":94},[],{"trials":789,"activeCount":94},[],{"trials":791,"activeCount":94},[792],{"nctId":793,"briefTitle":794,"status":723,"phases":795,"primaryCompletion":796,"completion":796,"start":752,"enrollment":24,"conditions":797,"interventions":804},"NCT01749111","Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis",[85],"2016-08",[798,799,800,801,802,803],"Acute Myelogenous Leukemia","Acute Lymphoid Leukemia","Myeloproliferative Disease","Myelodysplastic Syndrome","Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia",[782,805],"ARM B Calcineurin inhibitor and methotrexate",{"trials":807,"activeCount":94},[],{"trials":809,"activeCount":94},[],{"intervention":805,"totalTrials":90,"cells":811},{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":824,"NA":826},{"trials":813,"activeCount":94},[],{"trials":815,"activeCount":94},[],{"trials":817,"activeCount":94},[],{"trials":819,"activeCount":94},[820],{"nctId":793,"briefTitle":794,"status":723,"phases":821,"primaryCompletion":796,"completion":796,"start":752,"enrollment":24,"conditions":822,"interventions":823},[85],[798,799,800,801,802,803],[782,805],{"trials":825,"activeCount":94},[],{"trials":827,"activeCount":94},[],{"intervention":829,"totalTrials":90,"cells":830},"Hydroxychloroquine + azithromycin",{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":851,"NA":853},{"trials":832,"activeCount":94},[],{"trials":834,"activeCount":94},[],{"trials":836,"activeCount":94},[],{"trials":838,"activeCount":94},[839],{"nctId":840,"briefTitle":841,"status":464,"phases":842,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":849},"NCT04321278","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)",[85],"2020-06-14","2020-03-28",440,[847,848],"Coronavirus Infections","Pneumonia, Viral",[829,850],"Hydroxychloroquine",{"trials":852,"activeCount":94},[],{"trials":854,"activeCount":94},[],{"intervention":850,"totalTrials":90,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":869,"NA":871},{"trials":858,"activeCount":94},[],{"trials":860,"activeCount":94},[],{"trials":862,"activeCount":94},[],{"trials":864,"activeCount":94},[865],{"nctId":840,"briefTitle":841,"status":464,"phases":866,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":867,"interventions":868},[85],[847,848],[829,850],{"trials":870,"activeCount":94},[],{"trials":872,"activeCount":94},[],{"intervention":874,"totalTrials":179,"cells":875},"Nivolumab",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":906,"PHASE4":908,"NA":910},{"trials":877,"activeCount":94},[],{"trials":879,"activeCount":94},[],{"trials":881,"activeCount":94},[882,895],{"nctId":883,"briefTitle":884,"status":464,"phases":885,"primaryCompletion":611,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":891},"NCT05081674","Brazilian Lung Immunotherapy Study",[84],"2023-07-30","2020-01-01",154,[890],"Lung Neoplasm",[892,893,874,894],"Alectinib","Pembrolizumab","Erlotinib",{"nctId":896,"briefTitle":897,"status":464,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":904},"NCT04271384","Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer",[84],"2023-11-15","2020-02-12",25,[903],"Non-small Cell Lung Cancer Stage I",[905],"nivolumab",{"trials":907,"activeCount":94},[],{"trials":909,"activeCount":94},[],{"trials":911,"activeCount":94},[],{"intervention":913,"totalTrials":90,"cells":914},"Induction Chemotherapy",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":916,"activeCount":94},[],{"trials":918,"activeCount":94},[],{"trials":920,"activeCount":94},[921],{"nctId":922,"briefTitle":923,"status":464,"phases":924,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":934},"NCT02084563","Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms",[84],"2014-12","2016-11","2012-10",455,[930,931,932,933],"Acute Myeloid Leukemia","Myeloproliferative Neoplasms","Myelodysplastic Syndromes","Myeloproliferative\u002FMyelodysplastic Neoplasm",[913,935,936,937,938,939],"Consolidation Chemotherapy","Autologous Stem Cell Transplantation","Allogeneic Stem Cell Transplantation","Low Dose Cytarabine","Decitabine",{"trials":941,"activeCount":94},[],{"trials":943,"activeCount":94},[],{"trials":945,"activeCount":94},[],{"intervention":935,"totalTrials":90,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":949,"activeCount":94},[],{"trials":951,"activeCount":94},[],{"trials":953,"activeCount":94},[954],{"nctId":922,"briefTitle":923,"status":464,"phases":955,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":956,"interventions":957},[84],[930,931,932,933],[913,935,936,937,938,939],{"trials":959,"activeCount":94},[],{"trials":961,"activeCount":94},[],{"trials":963,"activeCount":94},[],{"intervention":936,"totalTrials":90,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":967,"activeCount":94},[],{"trials":969,"activeCount":94},[],{"trials":971,"activeCount":94},[972],{"nctId":922,"briefTitle":923,"status":464,"phases":973,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":974,"interventions":975},[84],[930,931,932,933],[913,935,936,937,938,939],{"trials":977,"activeCount":94},[],{"trials":979,"activeCount":94},[],{"trials":981,"activeCount":94},[],{"intervention":937,"totalTrials":90,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":985,"activeCount":94},[],{"trials":987,"activeCount":94},[],{"trials":989,"activeCount":94},[990],{"nctId":922,"briefTitle":923,"status":464,"phases":991,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":992,"interventions":993},[84],[930,931,932,933],[913,935,936,937,938,939],{"trials":995,"activeCount":94},[],{"trials":997,"activeCount":94},[],{"trials":999,"activeCount":94},[],{"intervention":938,"totalTrials":90,"cells":1001},{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":1003,"activeCount":94},[],{"trials":1005,"activeCount":94},[],{"trials":1007,"activeCount":94},[1008],{"nctId":922,"briefTitle":923,"status":464,"phases":1009,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":1010,"interventions":1011},[84],[930,931,932,933],[913,935,936,937,938,939],{"trials":1013,"activeCount":94},[],{"trials":1015,"activeCount":94},[],{"trials":1017,"activeCount":94},[],{"intervention":939,"totalTrials":90,"cells":1019},{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1021,"activeCount":94},[],{"trials":1023,"activeCount":94},[],{"trials":1025,"activeCount":94},[1026],{"nctId":922,"briefTitle":923,"status":464,"phases":1027,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":1028,"interventions":1029},[84],[930,931,932,933],[913,935,936,937,938,939],{"trials":1031,"activeCount":94},[],{"trials":1033,"activeCount":94},[],{"trials":1035,"activeCount":94},[],{"intervention":892,"totalTrials":90,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1039,"activeCount":94},[],{"trials":1041,"activeCount":94},[],{"trials":1043,"activeCount":94},[1044],{"nctId":883,"briefTitle":884,"status":464,"phases":1045,"primaryCompletion":611,"completion":886,"start":887,"enrollment":888,"conditions":1046,"interventions":1047},[84],[890],[892,893,874,894],{"trials":1049,"activeCount":94},[],{"trials":1051,"activeCount":94},[],{"trials":1053,"activeCount":94},[],{"intervention":893,"totalTrials":90,"cells":1055},{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1057,"activeCount":94},[],{"trials":1059,"activeCount":94},[],{"trials":1061,"activeCount":94},[1062],{"nctId":883,"briefTitle":884,"status":464,"phases":1063,"primaryCompletion":611,"completion":886,"start":887,"enrollment":888,"conditions":1064,"interventions":1065},[84],[890],[892,893,874,894],{"trials":1067,"activeCount":94},[],{"trials":1069,"activeCount":94},[],{"trials":1071,"activeCount":94},[],{"intervention":894,"totalTrials":90,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1075,"activeCount":94},[],{"trials":1077,"activeCount":94},[],{"trials":1079,"activeCount":94},[1080],{"nctId":883,"briefTitle":884,"status":464,"phases":1081,"primaryCompletion":611,"completion":886,"start":887,"enrollment":888,"conditions":1082,"interventions":1083},[84],[890],[892,893,874,894],{"trials":1085,"activeCount":94},[],{"trials":1087,"activeCount":94},[],{"trials":1089,"activeCount":94},[],{"intervention":1091,"totalTrials":90,"cells":1092},"Oxybutynin",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1094,"activeCount":94},[],{"trials":1096,"activeCount":94},[],{"trials":1098,"activeCount":94},[],{"trials":1100,"activeCount":94},[],{"trials":1102,"activeCount":94},[],{"trials":1104,"activeCount":94},[1105],{"nctId":1106,"briefTitle":1107,"status":464,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT01956591","Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis",[],"2013-09","2007-09",1100,[1113],"Hyperhidrosis",[1091],{"intervention":1116,"totalTrials":90,"cells":1117},"Budesonide",{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1119,"activeCount":94},[],{"trials":1121,"activeCount":94},[],{"trials":1123,"activeCount":94},[],{"trials":1125,"activeCount":94},[],{"trials":1127,"activeCount":94},[],{"trials":1129,"activeCount":94},[1130],{"nctId":1131,"briefTitle":1132,"status":490,"phases":1133,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT02056379","Comparison Between Budesonide and Dexamethasone Treatments for Respiratory Discomfort After Extubation on Children",[87],"2015-03","2016-03","2014-03",70,[1139],"Stridor",[1116,1141],"Dexamethasone",{"intervention":1141,"totalTrials":90,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1145,"activeCount":94},[],{"trials":1147,"activeCount":94},[],{"trials":1149,"activeCount":94},[],{"trials":1151,"activeCount":94},[],{"trials":1153,"activeCount":94},[],{"trials":1155,"activeCount":94},[1156],{"nctId":1131,"briefTitle":1132,"status":490,"phases":1157,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":1158,"interventions":1159},[87],[1139],[1116,1141],{"intervention":1161,"totalTrials":90,"cells":1162},"Nusinersen Injectable Product",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1164,"activeCount":94},[],{"trials":1166,"activeCount":94},[],{"trials":1168,"activeCount":94},[],{"trials":1170,"activeCount":94},[],{"trials":1172,"activeCount":94},[],{"trials":1174,"activeCount":94},[1175],{"nctId":1176,"briefTitle":1177,"status":464,"phases":1178,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1184},"NCT04404764","Characterization of the Clinical-epidemiological Profile of Patients With SMA5q Types II and III: Observational Study",[],"2021-04-23","2020-05-27",155,[1183],"Spinal Muscular Atrophy",[1161],{"intervention":1186,"totalTrials":90,"cells":1187},"Statin",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1198},{"trials":1189,"activeCount":94},[],{"trials":1191,"activeCount":94},[],{"trials":1193,"activeCount":94},[],{"trials":1195,"activeCount":94},[],{"trials":1197,"activeCount":94},[],{"trials":1199,"activeCount":94},[1200],{"nctId":1201,"briefTitle":1202,"status":464,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1210},"NCT05285085","Real World Evidence Study of Statin Use in Brazil",[],"2021-12-15","2021-11-19",2133900,[20,1208,23,18,322,1209],"Myocardial Infarction","Dyslipidemias",[1186],{"intervention":1212,"totalTrials":90,"cells":1213},"semaglutide use",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1215,"activeCount":94},[],{"trials":1217,"activeCount":94},[],{"trials":1219,"activeCount":94},[],{"trials":1221,"activeCount":94},[],{"trials":1223,"activeCount":94},[],{"trials":1225,"activeCount":94},[1226],{"nctId":1227,"briefTitle":1228,"status":464,"phases":1229,"primaryCompletion":1230,"completion":682,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1235},"NCT06154486","Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study",[],"2023-06-19",30,[1233,1234],"Pneumonia, Aspiration","Anesthesia",[1212]]